 Pharmaceutical group Hutchmed China Ltd is in demand after news of a new trial for a key product. It has linked up with AstraZeneca PLC for a Phase II study for Orphathys savolitinib at the Beijing Cancer hospital, to determine its efficiency on patients with gastric cancer whose disease progressed after at least one line of standard therapy. 